Related Experiment Video
Updated: Jan 10, 2026

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
Combination Therapy of Resilience Intervention with Biologics in Crohn's Disease (CATHARSIS): Study protocol for a
Laurie Keefer1, Ryan Ungaro1, Ayanna Lewis1
1Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, Inflammatory Bowel Disease Center, 17 E. 102nd Street, New York, NY, United States of America.
Background:
Remission rates in Crohn's disease (CD) with standard therapies have plateaued in recent decades. There is a need to investigate more innovative strategies to raise the "therapeutic ceiling". Combining orthogonal treatments that target differing pathways of disease pathogenesis may maximize synergistic therapeutic efficacy. In particular, the addition of interventions that target the gut-brain axis warrant investigation. Our overarching goal is to demonstrate the value of a new "combination therapy" that addresses psychological and physical health simultaneously, targeting the gut-brain axis, to improve CD outcomes. We will test the efficacy of combining brain-gut behavior therapy with biologic treatment in a randomized, controlled clinical trial, following behavioral clinical trial guidelines for gastroenterology.
Methods:
We will recruit 170 adults with CD aged between 18 and 80 years starting an anti-tumor necrosis factor or anti-interleukin-23 medication. Participants will be randomized in a 1:1 ratio to receive a program of either brain-gut behavioral therapy (intervention group) or emotional support (time and attention control group). Both programs consist of seven sessions within a 12-week period. Patient-reported outcomes including well-being and disease activity will be measured at weeks 0, 12, 24, 36, and 52, with the primary outcomes reflected at week 24. Outcomes will be evaluated for group X time interactions.
Conclusions:
This trial will be the first of its kind to rigorously evaluate the efficacy of a treatment approach that combines brain-gut behavioral therapy and biologics for people with CD.
More Related Videos
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
07:34Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Drugs for Treatment of Ulcerative Colitis in IBD